Literature DB >> 12139450

Discovery of 2-phenylamino-imidazo[4,5-h]isoquinolin-9-ones: a new class of inhibitors of lck kinase.

Roger J Snow1, Mario G Cardozo, Tina M Morwick, Carl A Busacca, Yong Dong, Robert J Eckner, Stephen Jacober, Scott Jakes, Suresh Kapadia, Susan Lukas, Maret Panzenbeck, Gregory W Peet, Jeffrey D Peterson, Anthony S Prokopowicz, Rosemarie Sellati, Robert M Tolbert, Matt A Tschantz, Neil Moss.   

Abstract

An imidazo[4,5-h]isoquinolin-7,9-dione (1) was identified as an adenosine 5'-triphosphate competitive inhibitor of lck by high throughput screening. Initial structure-activity relationship studies identified the dichlorophenyl ring and the imide NH as important pharmacophores. A binding model was constructed to understand how 1 binds to a related kinase, hck. These results suggested that removing the gem-dimethyl group and flattening the ring would enhance activity. This was realized by converting 1 to the imidazo[4,5-h]isoquinolin-9-one (20), resulting in an 18-fold improvement in potency against lck and a 50-fold increase in potency in a cellular assay.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12139450     DOI: 10.1021/jm020113o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Synthesis of novel isoquinolinone and 1,2-dihydroisoquinoline scaffolds via Ugi reaction and ring opening reaction of furans.

Authors:  Fei Ji; Wen-bin Yi; Mu Sun; Mei-fang Lv; Chun Cai
Journal:  Mol Divers       Date:  2013-03-20       Impact factor: 2.943

2.  First cascade Mitsunobu reactions for the synthesis of 2-benzoxazole-N-phenyl and 2-benzimidazole-N-phenyl derivatives.

Authors:  Yu Yan; Qifei Zhong; Nan Zhao; Gang Liu
Journal:  Mol Divers       Date:  2011-11-30       Impact factor: 2.943

3.  Synthesis and cytotoxicity evaluation of novel pyrido[3,4-d]pyrimidine derivatives as potential anticancer agents.

Authors:  Linyi Wei; Sanjay V Malhotra
Journal:  Medchemcomm       Date:  2012-10       Impact factor: 3.597

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.